argenx NV ADR halted a late-stage study for its autoimmune disease treatment, causing a significant drop in stock price.
The company announced the cessation of this study, leading to a notable decline in its stock price. The stock closed at US$818.11, down 11.83% on the day, and has dropped 12.54% over the past week and 18.71% over the past month, reflecting growing investor concerns about the company's future prospects.
Advertisement
argenx NV ADR
ARGX.US
ARGX.US
argenx NV ADR
WealthAwesomeMarket cap
$58.39B
P/E
35.4x
52W high
$1072.75
52W low
$661.85
1W change
-12.54%
Beta
-0.04
Analyst Price Targets
Based on 11 analysts covering ARGX · as of Oct 5, 2026
Wall Street analysts forecast ARGX stock price to rise 44.2% over the next 12 months.
Consensus
Buy4.45 / 5.00
Avg. Target
C$1180.26
+44.2% Upside
Previously C$1180.17 on Oct 1, 2026
Current Price
C$818.63
Last close
Analyst Breakdown (11 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ARGX's historical volatility
30-Day Vol
42.3%
Annualized
90-Day Vol
47.9%
Annualized
Trend (90d)
-22.1%
Annualized drift
90d Mean
C$756.41
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$797.34 | C$689.17 – C$922.49 |
| 60 trading days | C$776.60 | C$631.91 – C$954.44 |
| 90 trading days | C$756.41 | C$587.60 – C$973.71 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The halt in the study raises questions about the company's future growth prospects in the autoimmune disease sector.
ARGX Shares Fall 11.83% on Trial Halt
Today's trading volume was 260,773 shares, marking an 8.84x increase compared to the 20-day average of 277,471 shares.
Bull case
Despite the recent setback, analysts remain optimistic. They have set an average target price of US$1180.26, indicating potential for recovery.
Bear case
The termination of the trial has erased an estimated $3.5 billion opportunity, adding to concerns about the company's valuation and market performance.
Trial Halt Announcement
Advertisement
On October 9, argenx NV ADR announced the stoppage of its late-stage study for the autoimmune disease treatment, which led to significant sell-offs in its stock. Before the announcement, the stock was trading around US$926.00, but it closed at US$818.11 after the news broke, marking an 11.83% decrease in a single day and highlighting the immediate impact of the halted study on investor sentiment.
Stock Performance and Trading Volume
Following the announcement, ARGX shares experienced significant volatility. The trading volume surged to 260,773 shares, which is 8.84 times the 20-day average volume of 277,471 shares. Over the last month, the stock has declined by 18.71%, and year-to-date, it is down 2.54%. Currently, the stock is trading below both its 50-day moving average of US$958.57 and its 200-day moving average of US$852.28, indicating bearish momentum.
Future Implications and Analyst Outlook
The cessation of the trial has erased an estimated $3.5 billion potential opportunity for argenx, raising questions about its future growth trajectory. Despite this setback, analysts maintain a positive outlook, with an average target price of US$1180.26, reflecting an implied upside of 44.3% from the current trading price. With a P/E ratio of 35.38 and a market cap of approximately US$58.39 billion, investors will be closely monitoring the company's next steps.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
